Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer

Journal of Surgical Research

Volumn 170, Issue 2, 2011, Pages 169-178

  Girgis, Mark D ^a,c   Kenanova, Vania ^b   Olafsen, Tove ^b   McCabe, Katelyn E ^b   Wu, Anna M ^b   Tomlinson, James S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

antibody; CA19 9; diabody; pancreas cancer; PET imaging; tumor targeting

Indexed keywords

CA 19-9 ANTIGEN; CA 19-9 DIABODY; CA 19-9 DIABODY I 124; CANCER ANTIBODY; DNA; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CANCER SCINTISCANNING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOFLUORESCENCE; ISOTOPE LABELING; MICRO POSITRON EMISSION TOMOGRAPHY; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS SCINTISCANNING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; RADIOACTIVITY; RADIOIODINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CA-19-9 ANTIGEN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN FRAGMENTS; IODINE RADIOISOTOPES; MICE; MULTIPLE MYELOMA; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN ENGINEERING; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 80052806316     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2011.03.065     Document Type: Article

References (42)

1. American Cancer Society. Cancer facts and figures. New York: American Cancer Society, p. v.
2. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277
3. J.L. Cameron, T.S. Riall, and J. Coleman One thousand consecutive pancreaticoduodenectomies Ann Surg 244 2006 10
4. K.K. Kazanjian, O.J. Hines, and J.P. Duffy Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: The influence of operative blood loss Arch Surg 143 2008 1166
5. A. Richter, M. Niedergethmann, and J.W. Sturm Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-Year experience World J Surg 27 2003 324
6. M.K. Kalra, M.M. Maher, and P.R. Mueller State-of-the-art imaging of pancreatic neoplasms Br J Rsadiol 76 2003 857
7. S.P. Kauhanen, G. Komar, and M.P. Seppanen A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer Ann Surg 250 2009 957
8. P. Klever, R. Bares, and J. Fass PET with fluorine-18 deoxyglucose for pancreatic disease Lancet 340 1992 1158
9. D.M. Rose, D. Delbeke, and R.D. Beauchamp 18-Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer Ann Surg 229 1999 729 discussion 737
10. D.V. Sahani, Z.K. Shah, and O.A. Catalano Radiology of pancreatic adenocarcinoma: Current status of imaging J Gastroenterol Hepatol 23 2008 23
11. M.A. Pysz, S.S. Gambhir, and J.K. Willmann Molecular imaging: Current status and emerging strategies Clin Radiol 65 2010 500
12. V. Kenanova, and A.M. Wu Tailoring antibodies for radionuclide delivery Expert Opin Drug Deliv 3 2006 53
13. V. Kenanova, T. Olafsen, and L.E. Williams Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: Optimal pharmacokinetics for therapy Cancer Res 67 2007 718
14. G. Sundaresan, P.J. Yazaki, and J.E. Shively 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice J Nucl Med 44 2003 1962
15. L.E. Williams, A.M. Wu, and P.J. Yazaki Numerical selection of optimal tumor imaging agents with application to engineered antibodies Cancer Biother Radiopharm 16 2001 25
16. C. Haglund, J. Lindgren, and P.J. Roberts Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis Br J Cancer 53 1986 189
17. T.S. Loy, S.C. Sharp, and C.J. Andershock Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas. An immunohistochemical study of 527 cases Am J Clin Pathol 99 1993 726
18. J. Makovitzky The distribution and localization of the monoclonal antibody-defined antigen 19-9 (CA19-9) in chronic pancreatitis and pancreatic carcinoma. An immunohistochemical study Virchows Arch B Cell Pathol Incl Mol Pathol 51 1986 535
19. G. Ohshio, K. Ogawa, and H. Kudo Immunohistochemical studies on the localization of cancer associated antigens DU-PAN-2 and CA19-9 in carcinomas of the digestive tract J Gastroenterol Hepatol 5 1990 25
20. K. Yamaguchi, M. Enjoji, and M. Tsuneyoshi Pancreatoduodenal carcinoma: A clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9 J Surg Oncol 47 1991 148
21. M. Herlyn, M. Blaszczyk, and J. Bennicelli Selection of monoclonal antibodies detecting serodiagnostic human tumor markers J Immunol Methods 80 1985 107
22. H. Koprowski, Z. Steplewski, and K. Mitchell Colorectal carcinoma antigens detected by hybridoma antibodies Somatic Cell Genet 5 1979 957
23. B.F. Atkinson, C.S. Ernst, and M. Herlyn Gastrointestinal cancer-associated antigen in immunoperoxidase assay Cancer Res 42 1982 4820
24. J.L. Magnani, Z. Steplewski, and H. Koprowski Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin Cancer Res 43 1983 5489
25. R. Kannagi Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression - the Warburg effect revisited Glycoconj J 20 2004 353
26. R. Kannagi Carbohydrate antigen sialyl Lewis a - its pathophysiological significance and induction mechanism in cancer progression Chang Gung Med J 30 2007 189
27. J.L. Magnani The discovery, biology, and drug development of sialyl Lea and sialyl Lex Arch Biochem Biophys 426 2004 122
28. Y. Chen, S. Clark, and T. Wong Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models Cancer Res 67 2007 4924
29. S. Dubel, F. Breitling, and P. Fuchs Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers J Immunol Methods 175 1994 89
30. D.W. Tonge, J.F. Hennam, and A.R. Greene Cloning and characterization of 1116NS19.9 heavy and light chain cDNAs and expression of antibody fragments in Escherichia coli Year Immunol 7 1993 56
31. C.R. Bebbington, G. Renner, and S. Thomson High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker Biotechnology (NY) 10 1992 169
32. G. Galfre, and C. Milstein Preparation of monoclonal antibodies: Strategies and procedures Methods Enzymol 73 1981 3
33. V. Kenanova, T. Olafsen, and D.M. Crow Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments Cancer Res 65 2005 622
34. A.P. Richardson, P.J. Mountford, and A.C. Baird An improved iodogen method of labelling antibodies with 123I Nucl Med Commun 7 1986 355
35. M. Defrise, P.E. Kinahan, and D.W. Townsend Exact and approximate rebinning algorithms for 3-D PET data IEEE Trans Med Imaging 16 1997 145
36. A.M. Loening, and S.S. Gambhir AMIDE: A free software tool for multimodality medical image analysis Mol Imaging 2 2003 131
37. S. Ahlgren, H. Wallberg, and T.A. Tran Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine J Nucl Med 50 2009 781
38. G.H. Albers, G. Fleuren, and M.J. Escribano Immunohistochemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma Am J Clin Pathol 90 1988 17
39. W.H. Allum, H.J. Stokes, and F. Macdonald Demonstration of carcinoembryonic antigen (CEA) expression in normal, chronically inflamed, and malignant pancreatic tissue by immunohistochemistry J Clin Pathol 39 1986 610
40. D.V. Gold, D.M. Goldenberg, and H. Karacay A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma Cancer Res 68 2008 4819
41. T. Olafsen, G.J. Tan, and C.W. Cheung Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting Protein Eng Des Sel 17 2004 315
42. L.G. Presta Engineering of therapeutic antibodies to minimize immunogenicity and optimize function Adv Drug Deliv Rev 58 2006 640